|Description||Inflammatory/immune disease medications|
|Venture Round, 1/2007 |
Desjardins Venture Capital
BDC Venture Capital
|Series A, 5/2009 |
|Partial Close, 5/2009 ||$5.89M|
Osprey Pharmaceuticals USA is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases.
The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases.
The Companyâ€™s lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy.